miR-155 and miR-92 levels in ALL, post-transplant aGVHD, and CMV: possible new treatment options
CONCLUSION: Our study suggests that the plasma signature of microRNA expression may act as a powerful marker for diagnosis and prognosis, providing knowledge outside cytogenetics. Elevation of miR-155 in plasma can be a beneficial therapeutic target for ALL patients, with consideration of higher plasma levels of miR-92 and miR-155 in CMV + and post-HSCT aGVHD patients.PMID:37332027 | DOI:10.1186/s43046-023-00174-3
Source: J Egypt Natl Canc In... - Category: Cancer & Oncology Authors: Mahdiyar Iravani Saadi Mohsen Nikandish Zahra Ghahramani Fatemeh Mardani Valandani Maryam Ahmadyan Fakhroddin Hosseini Zahra Rahimian Heeva Jalali Fataneh Tavasolian Ehsan Nabi Abdolyousefi Nadiya Kheradmand Mani Ramzi Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Cytomegalovirus | Egypt Health | Endemics | Hematology | Iran Health | Leukemia | Men | Middle East Health | Statistics | Stem Cell Therapy | Stem Cells | Study | Transplants